Apart from genetic evidence, we further showed that high intratumoral FGFR1 expression was also associated with shorter OS and DFS, lending support to the proposition that FGFR1 amplification predicts poor clinical outcome of ESCC patients. The gene discussed is FGFR1; the disease is esophageal squamous cell carcinoma.